Division of Clinical Epidemiology and Evaluative Sciences Research, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Department of Psychology "Renzo Canestrari," University of Bologna, Bologna, Italy.
Psychother Psychosom. 2022;91(1):8-35. doi: 10.1159/000521288. Epub 2022 Jan 6.
The present critical review was conducted to evaluate the clinimetric properties of the Charlson Comorbidity Index (CCI), an assessment tool designed specifically to predict long-term mortality, with regard to its reliability, concurrent validity, sensitivity, incremental and predictive validity. The original version of the CCI has been adapted for use with different sources of data, ICD-9 and ICD-10 codes. The inter-rater reliability of the CCI was found to be excellent, with extremely high agreement between self-report and medical charts. The CCI has also been shown either to have concurrent validity with a number of other prognostic scales or to result in concordant predictions. Importantly, the clinimetric sensitivity of the CCI has been demonstrated in a variety of medical conditions, with stepwise increases in the CCI associated with stepwise increases in mortality. The CCI is also characterized by the clinimetric property of incremental validity, whereby adding the CCI to other measures increases the overall predictive accuracy. It has been shown to predict long-term mortality in different clinical populations, including medical, surgical, intensive care unit (ICU), trauma, and cancer patients. It may also predict in-hospital mortality, although in some instances, such as ICU or trauma patients, the CCI did not perform as well as other instruments designed specifically for that purpose. The CCI thus appears to be clinically useful not only to provide a valid assessment of the patient's unique clinical situation, but also to demarcate major diagnostic and prognostic differences among subgroups of patients sharing the same medical diagnosis.
本综述旨在评估 Charlson 共病指数 (CCI) 的临床计量学特性,CCI 是一种专门用于预测长期死亡率的评估工具,涉及可靠性、同期效度、灵敏度、增量和预测效度。CCI 的原始版本已经针对不同的数据来源(ICD-9 和 ICD-10 代码)进行了改编。CCI 的组内信度被发现极好,自我报告和医疗记录之间的一致性极高。CCI 还被证明与许多其他预后量表具有同期效度,或者导致一致的预测。重要的是,CCI 的临床计量学灵敏度已在多种医疗条件下得到证明,CCI 的逐步增加与死亡率的逐步增加相关。CCI 还具有增量有效性的临床计量学特性,即通过将 CCI 添加到其他测量中可以提高整体预测准确性。它已被证明可以预测不同临床人群的长期死亡率,包括内科、外科、重症监护病房(ICU)、创伤和癌症患者。它还可能预测住院期间的死亡率,尽管在某些情况下,如 ICU 或创伤患者,CCI 的表现不如其他专门为此目的设计的仪器。因此,CCI 不仅在提供对患者独特临床情况的有效评估方面具有临床意义,而且在为具有相同医疗诊断的患者亚组划定主要诊断和预后差异方面也具有临床意义。